U.S. Hospitality Stock News

AngioDynamics (ANGO) is back on investors’ radar after its Med Tech platforms helped deliver stronger quarterly results, prompting management to raise full year revenue and profitability guidance while outlining an upcoming CEO transition. See our latest analysis for AngioDynamics. Even with the raised guidance and progress in Med Tech platforms, AngioDynamics’ 7 day share price return of 21.73% and 30 day share price return of 23.63% suggest recent momentum has faded, aligning with a 1 year...

As the U.S. stock market experiences a surge, with the S&P 500 reaching new all-time highs and major indexes poised for weekly gains, investors are keenly observing opportunities amidst mixed economic signals like a falling unemployment rate. In this environment of fluctuating indices and evolving economic policies, identifying stocks that may be trading below their estimated value could offer potential avenues for growth and diversification.

As the U.S. stock market experiences a surge, with the S&P 500 reaching new all-time highs and major indexes poised for weekly gains, investors are keenly observing growth companies that combine robust performance with substantial insider ownership. In this thriving economic landscape, stocks with high insider ownership can be particularly appealing as they often indicate strong confidence from those who know the company best, aligning their interests with those of external shareholders.

As the U.S. stock market experiences a surge, with major indexes like the S&P 500 reaching new all-time highs, investors are increasingly looking for opportunities beyond traditional large-cap stocks. Despite its somewhat outdated connotation, the term "penny stock" continues to highlight investment potential in smaller or newer companies that may offer significant returns when backed by strong financials. In this article, we explore three penny stocks that demonstrate balance sheet...

As the U.S. stock market continues to soar, with the S&P 500 reaching new all-time highs following a drop in unemployment rates, investors are keenly observing opportunities within the small-cap sector. In this dynamic environment, identifying promising stocks requires a focus on companies that can navigate economic shifts and capitalize on emerging trends.

When we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics...

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

AZZ (AZZ) has put up a busy run of quarters ahead of its Q3 2026 report, with Q3 fiscal revenue at US$425.7 million and basic EPS of US$1.37, sitting alongside trailing 12 month revenue of about US$1.6 billion and EPS of US$10.73. Over recent periods the company has seen quarterly revenue move from US$403.7 million in Q3 2025 to US$351.9 million in Q4 2025, then into the US$422.0 million to US$425.7 million range in Q1 to Q3 2026, while basic EPS has ranged from US$0.68 in Q4 2025 to US$5.71...

If you are wondering whether UDR is priced attractively today, this article walks through what the current numbers suggest about the stock's value. UDR recently closed at US$37.32, with returns of 1.7% over the last week, 6.9% over the last month, 1.7% year to date, and a 5.4% decline over the past year. This gives a mixed picture of recent performance. Recent coverage around UDR has focused on how investors are reassessing listed residential real estate, with pricing and capital allocation...

Arbe Robotics recently announced at CES 2026 that it is combining its automotive-grade ultra‑HD radar with NVIDIA’s accelerated computing to create an AI-based perception platform designed for hands-off, eyes-off driving, featuring over 20,000 detections per frame and more than 300 meters of range in varied weather conditions. A distinctive aspect of this development is how the dense radar point cloud, processed on NVIDIA’s in-vehicle computing, is being used to build AI-based occupancy...

Q3 revenue surprise puts XPEL (XPEL) back in focus Recent attention on XPEL (XPEL) stems from its Q3 results, where revenue growth surpassed expectations while earnings per share came in below forecasts. This has prompted investors to reassess the trade off between sales momentum and profitability. See our latest analysis for XPEL. At a share price of $54.63, XPEL has climbed sharply in recent months, with a 90 day share price return of 61.18% and a 1 year total shareholder return of 39.35%...

For investors wondering whether Karman Holdings at around US$101.28 represents an opportunity or is already fully valued, this article walks through what the numbers may indicate about the stock. The share price has been active recently, with returns of 38.4% over the past 7 days, 58.9% over the past 30 days and 31.8% year to date. These movements can influence how you think about potential upside and risk. Recent coverage of Karman Holdings has focused on its listing on the NYSE and growing...

Allot (ALLT) is back in focus after reports that its Cybersecurity as a Service business delivered about 60% year over year growth in annual recurring revenue in the third quarter of 2025. See our latest analysis for Allot. That SECaaS momentum comes alongside a $10.86 share price, a 7 day share price return of 10.48% and a 1 year total shareholder return of 50.21%, hinting at building momentum despite a 5.57% 1 day pullback. If Allot’s recent move has caught your eye, it could be a good...

Diversified Healthcare Trust (DHC) has set out a fresh course with three linked moves: large non core property sales, full repayment of its 2026 notes, and a broad reset of senior housing operations. See our latest analysis for Diversified Healthcare Trust. Those asset sales, debt repayment and senior housing changes arrive after a sharp shift in investor sentiment, with the share price at US$5.40 and a 90 day share price return of 33.33%, alongside a very large 3 year total shareholder...

Oculis Holding (NasdaqGM:OCS) is back on investor radars after its neuroprotective candidate Privosegtor received FDA breakthrough therapy designation for optic neuritis, supported by Phase 2 ACUITY data and advancement into registrational PIONEER trials. See our latest analysis for Oculis Holding. The FDA breakthrough therapy news has arrived alongside a 10.3% 7 day share price return and a 10.2% year to date share price return, while the 1 year total shareholder return of 17.8% and very...

In early January 2026, LifeMD announced it is now offering Novo Nordisk’s newly FDA-approved Wegovy (semaglutide) pill through its nationwide telehealth platform, expanding virtual access to an oral GLP-1 option for chronic weight management and cardiovascular health at cash-pay prices starting from US$149 per month for eligible patients. This move deepens LifeMD’s collaboration with Novo Nordisk and positions the company more firmly in the fast-growing obesity care segment by pairing...

It's nice to see the Oxford Industries, Inc. ( NYSE:OXM ) share price up 13% in a week. But over the last three years...

Expro Group Holdings N.V.'s ( NYSE:XPRO ) price-to-earnings (or "P/E") ratio of 24.5x might make it look like a sell...

Build-A-Bear Workshop (NYSE:BBW) has had a great run on the share market with its stock up by a significant 26% over...

Phathom Pharmaceuticals recently completed a roughly US$130.0 million follow-on offering of common stock and pre-funded warrants, alongside new shelf registrations covering additional common stock and other securities, and issued earnings guidance indicating expected net revenues of about US$57.0 million–US$58.0 million for fourth quarter 2025 and US$174.5 million–US$175.5 million for full-year 2025, with operating profitability targeted in the second half of 2026 excluding stock-based...

If you are wondering whether Tuya's current share price lines up with its underlying worth, you are not alone. This article is built to help you size up what you are really paying for. Tuya's stock last closed at US$2.22, with returns of 5.2% over the past week, a 3.5% decline over the last 30 days, and gains of 1.4% year to date and 37.9% over the last year, while the three year return sits at a 7.9% decline. Recent headlines around Tuya have focused on its role as a software provider in...

If you are wondering whether Cactus shares still offer value at around US$51.37, you are not alone. This article focuses on what that price could mean for long term investors. The stock has recently moved, with returns of 12.5% over the last 7 days, 12.4% over the last 30 days, 9.2% year to date and an overall 12.5% decline over the last year, while the 5 year return stands at 85.5% and the 3 year return at a 3.3% decline. These swings have put Cactus back on the radar for investors who...

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

It's not a stretch to say that Taboola.com Ltd.'s ( NASDAQ:TBLA ) price-to-sales (or "P/S") ratio of 0.7x right now...